Module 5: Amyloidosis, POEMS, and Castleman Disease
This learning activity has been designated for 1.25 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.
Learning Objectives
Upon completion of this education program the participant should be able to:
- Describe and discuss the presentation, diagnosis, and baseline evaluation of systemic light chain (AL) amyloidosis;
- Identify the goal of therapy for AL amyloidosis and discuss its therapeutic options;
- Describe and discuss the clinical features, diagnostic criteria, and management of the POEMS syndrome;
-
Compare the various presentations of Castleman disease and their management.
Target Audience
This learning activity is intended for medical oncologists, hematologists,
stem cell transplant physicians, and other interested healthcare professionals who treat and manage myeloma and related diseases in the hematology/oncology and transplant patient settings.
Release Date: April 09, 2009
Expiration date: April 09, 2010
(*Please check this box to proceed - required)
Start the Module